Oral Micronized Progesterone Pre-Surgery Hold Window: Clinical Guidance

Oral micronized progesterone (brand name Prometrium; generic bioidentical progesterone, USP-grade, in a peanut-oil-based soft-gel capsule) is prescribed alongside estrogen in menopausal hormone therapy and in some gender-affirming hormone regimens, to protect the endometrium from unopposed estrogen stimulation. It is not the same molecule as synthetic progestins such as medroxyprogesterone acetate, and it is not injectable progesterone or a compounded topical cream, both of which have different absorption profiles.

Most surgical and anesthesia teams ask patients to pause oral micronized progesterone, together with any paired oral estrogen, for approximately 4 to 6 weeks before elective surgery that involves general anesthesia or an expected period of significant immobility. The rationale is additive venous thromboembolism (VTE) risk during the perioperative period, not a direct pharmacologic conflict with anesthetic drugs. Minor procedures under local anesthesia with rapid return to full activity typically do not require any hold. This is a widely followed clinical practice pattern rather than a single binding FDA rule, and exact hold lengths vary by institution, procedure, and individual risk factors, so the specific number your surgical team gives you should override any general figure on this page.

What is established, what is plausible, and what is not established

Established: Surgery and post-operative immobility independently raise VTE risk. Combined oral hormone therapy (estrogen plus a progestogen) has been associated with higher VTE risk than non-use in observational research, and transdermal estrogen delivery has generally been associated with a smaller VTE signal than oral estrogen, a distinction referenced in menopause society guidance. Oral micronized progesterone undergoes substantial hepatic first-pass metabolism, unlike vaginal or transdermal delivery.

Plausible but unproven at the level of a specific number: That a 4-to-6-week hold produces a precisely quantifiable reduction in perioperative VTE events for this specific drug, as opposed to hormone therapy in general. Trial-level evidence isolating oral micronized progesterone's incremental contribution to perioperative VTE risk, separate from the paired estrogen, is limited.

Not established from the material available for this article: Any specific relative-risk figure, trial patient count, or named-trial statistic cited in earlier drafts of this guidance could not be independently confirmed against a verified primary source at the time of writing. Where a precise number appears below, it is flagged as requiring verification before publication rather than stated as settled fact.

Why the hold exists: the mechanism, in plain terms

Surgery itself creates a temporary pro-clotting state. General anesthesia, immobility on the table, post-operative bed rest, tissue trauma, and inflammatory signaling all shift the coagulation system toward clot formation. Exogenous sex hormones can add to that shift. Progestogens are thought to modestly affect natural anticoagulant proteins (including protein S) and, when combined with estrogen, to potentiate estrogen-driven increases in several clotting factors. The hold window is designed to let circulating hormone effects on coagulation settle before adding the further thrombogenic stress of an operation.

Because oral micronized progesterone passes through the liver in high concentration before reaching general circulation (first-pass metabolism), and the liver is also where most clotting factors are made, the oral route is treated with more caution than vaginal or transdermal progesterone, which largely bypass this first pass. This is a pharmacokinetic and mechanistic argument, not a claim backed here by a specific comparative trial number; the underlying idea appears in menopause and thrombosis literature but a precise quantitative comparison for progesterone specifically should be verified against the primary literature before being repeated as a fixed figure.

The FDA-approved regimen, for orientation

The current FDA-approved Prometrium label describes two standard dosing patterns: 200 mg nightly for 12 days of a 28-day cycle (cyclic use, paired with continuous estrogen) or 100 mg nightly (continuous combined use), and the label notes that food, particularly a high-fat meal, increases absorption (according to the FDA-approved prescribing information for Prometrium; readers should confirm the current label revision before relying on exact figures, since labels are periodically updated). The label's pharmacokinetic data support the general point that oral bioavailability is low and variable, which is one reason surgical teams want an explicit stop date rather than an estimate based on drug half-life alone.

The elimination half-life of oral micronized progesterone is commonly cited as roughly 16 to 18 hours, meaning the drug itself clears from the body within a matter of days. The 4-to-6-week hold is not about waiting for the drug to leave the bloodstream. It is about waiting for the hormone's downstream effect on coagulation-factor balance to normalize, which clinical practice treats as a slower process than pharmacokinetic clearance.

A decision framework for hold length

The single fixed number "4 to 6 weeks" is a reasonable default, but it is not the right answer for every procedure. The table below is a working decision aid, not a validated clinical algorithm, and it should be used to structure the conversation with your surgeon and prescriber rather than to self-determine a stop date.

Exceptions that override this table:

• Patients already on therapeutic anticoagulation for a prior VTE or atrial fibrillation: the anticoagulation bridging plan generally takes priority, and the hormone hold decision becomes secondary to that plan.
• Patients with significant hepatic impairment: metabolite clearance may be altered, and a pharmacist or hepatology consult is reasonable before finalizing a hold date.
• Patients with a history of complex endometrial hyperplasia: restart should be contingent on endometrial reassessment, not just a calendar date.
• Cyclic (not continuous) dosing users: if a patient is already in the untreated part of her monthly cycle when surgery is booked, the effective hold before her next progesterone dose may already be partly underway; this does not shorten the hold on the estrogen side.

Next step for the reader: bring this table to the pre-operative visit, ask the surgical team which row applies to your specific procedure, and get the exact stop date and restart criteria in writing rather than relying on a general rule.

Endometrial risk during a brief hold

A 4-to-6-week hold in a patient who also stops her paired estrogen at the same time is not expected to create meaningful endometrial risk, because unopposed estrogen exposure, the actual driver of endometrial stimulation, does not occur when both hormones are held together. Endometrial risk becomes a real question only if estrogen is continued while progesterone alone is paused, which is not the standard perioperative practice; the two hormones are typically stopped and restarted on the same schedule.

For patients who complete a hold of 6 weeks or longer, some clinicians choose a brief endometrial reassessment before restart, particularly if there was any abnormal bleeding during the pause: a transvaginal ultrasound endometrial stripe measurement and a symptom review are reasonable options. Most patients who complete a routine surgical hold without bleeding or new symptoms can resume their standard dose without additional imaging, especially if recent endometrial surveillance was already normal, but this is a matter of clinical judgment rather than a fixed rule.

The paired estrogen: a linked decision, not a separate one

Oral micronized progesterone is almost always prescribed together with an estrogen, and the two hormones are managed as a pair perioperatively. Holding progesterone while continuing estrogen defeats the purpose of the hold (unopposed estrogen exposure) and offers no VTE benefit, since estrogen is generally considered the larger driver of the VTE signal in combined therapy. Observational research has associated oral estrogen with a higher VTE risk than transdermal estradiol at typical low-to-moderate transdermal doses, which is one reason some patients who need continued hormone support closer to surgery may discuss switching formulations with their prescriber well in advance rather than at the pre-operative visit. The practical instruction most patients receive: stop both hormones on the same date, hold for the agreed window, and restart both together once mobility criteria are met.

Pharmacokinetics relevant to perioperative planning

Oral micronized progesterone is absorbed in the small intestine and undergoes extensive first-pass hepatic metabolism, which the FDA label associates with low and food-dependent bioavailability; a high-fat meal materially increases absorption, and this variability is one reason serum levels in real-world use can differ from fasting pharmacokinetic study conditions (as described in the FDA-approved prescribing information). Reported peak serum levels occur within a few hours of ingestion, and elimination is described in the pharmacokinetic literature as substantially complete within several days. Metabolites are renally excreted; patients with significant hepatic impairment may need individualized pharmacist input before a hold is finalized, since metabolite handling could differ.

Oral micronized progesterone produces neurosteroid metabolites, including allopregnanolone, which act on GABA-A receptors. This has led to a theoretical and small observational discussion of reduced anesthetic induction-agent requirements in patients on progesterone-based regimens. The evidence here is limited and the effect, if real, appears small; this claim should be treated as an area of ongoing observation rather than an established clinical rule, and any specific published effect size should be verified against the original report before being used to guide anesthetic dosing. In practice, the actionable point is simpler: current hormone therapy, including oral micronized progesterone, should be listed clearly on pre-operative medication reconciliation so the anesthesia team has the full picture.

VTE prevention during the hold: hormone hold and prophylaxis are not interchangeable

For patients with higher baseline VTE risk (prior VTE, known thrombophilia, obesity, prolonged immobility expected after surgery), stopping hormone therapy alone is not considered adequate perioperative VTE prevention. Guideline bodies addressing perioperative VTE prevention generally recommend mechanical prophylaxis (compression devices) and, in higher-risk patients, pharmacologic prophylaxis such as low-molecular-weight or unfractionated heparin, independent of hormone status. The hormone hold and pharmacologic prophylaxis address the same underlying risk from different angles and are additive, not alternatives to each other.

Restarting after surgery

Most patients restart oral micronized progesterone (and the paired estrogen) roughly 2 to 4 weeks after surgery, once they are fully ambulatory and there is no active VTE, wound hematoma, or unexpected bleeding. Procedures with a longer expected rehabilitation course, particularly some orthopedic surgeries, may push restart to around 6 weeks or until physical therapy clears full weight-bearing activity. Restart at the pre-operative dose is standard; there is no established clinical rationale for a dose "ramp-up" after a routine hold of this length in a patient who was previously stable on therapy. Restart should be an explicit order from the prescribing clinician tied to a mobility milestone, not an assumption the patient makes on her own.

Vasomotor symptoms during the hold

Stopping progesterone alone rarely causes dramatic hot flashes, since vasomotor symptoms are primarily driven by estrogen withdrawal. Because both hormones are typically held together, most patients do experience some recurrence of hot flashes or night sweats during the hold window; this is an expected tradeoff of safe surgical preparation, not a sign of a problem.

FDA-approved non-hormonal options for moderate-to-severe vasomotor symptoms include fezolinetant (Veozah), a neurokinin-3 receptor antagonist approved in 2023, and low-dose paroxetine 7.5 mg (Brisdelle), the SSRI specifically approved for this indication. Gabapentin is used off-label for sleep-disrupting hot flashes and has support from randomized trials, though it is not FDA-approved for this specific use. Specific effect sizes for these agents (percentage reduction in hot flash frequency, number-needed-to-treat) were not independently verified for this draft and should be confirmed against the original trial publications before being quoted to patients as precise figures. The practical point for surgical planning is to raise bridging options at the same appointment where the hold is discussed, not as a late add-on.

Special populations

History of complex endometrial hyperplasia: the VTE-driven hold still applies, but restart should be contingent on endometrial reassessment (ultrasound and, if indicated, biopsy) rather than a fixed calendar date, given the underlying diagnosis.

Concurrent therapeutic anticoagulation: in patients already anticoagulated for a prior VTE or atrial fibrillation, the surgical team's anticoagulation bridging plan generally takes precedence over the hormone hold decision, and the two should be coordinated rather than managed separately.

Gender-affirming hormone therapy: transgender and non-binary patients using oral micronized progesterone as part of gender-affirming care are subject to the same pharmacokinetic and VTE considerations discussed above; long operative times and extensive tissue dissection in some gender-affirming surgeries are consistent with the higher end of the risk categories in the framework table.

The patient conversation

A useful pre-operative conversation covers four points: the specific hold start date, why the hold exists (VTE risk from immobility, not drug toxicity), what symptoms to expect and what bridging options exist, and the restart criteria tied to a mobility milestone rather than a fixed number of days. Framing the hold as a temporary, safety-driven pause, rather than a permanent stop, tends to improve follow-through on the restart step. Guideline bodies addressing menopausal hormone therapy generally recommend that hormone therapy decisions, including around procedures, be individualized to the patient's cardiovascular, VTE, and breast cancer risk profile; readers should ask their prescriber how their personal risk factors modify the default hold length in the table above.

Documentation matters as much as the hold itself

Perioperative hormone holds are frequently missed on medication reconciliation because patients and staff do not always think of a hormone capsule as a "surgical" medication. Two failure modes are common in practice: a patient keeps taking progesterone because no one explicitly told her to stop, or a patient never restarts because no clinician generated a restart order after discharge. Documenting the hold and the restart date in the surgical chart, the prescriber's note, and the patient's own medication list addresses both failure modes directly.

Questions readers actually ask

How long before surgery should I stop oral micronized progesterone? For elective surgery involving general anesthesia or an overnight stay, 4 to 6 weeks is the commonly used default, but the exact number depends on your specific procedure and risk factors. Confirm the exact date with your surgical team and prescriber rather than relying on a general figure.

Why does progesterone need to be stopped before surgery if it isn't a blood thinner interaction with anesthesia itself? The concern is additive VTE risk from surgery-related immobility combined with hormone therapy's effect on coagulation factors, not a direct pharmacologic clash with anesthetic drugs.

What happens to endometrial protection during the hold? If both estrogen and progesterone are stopped together, which is standard practice, endometrial stimulation is not expected to be a meaningful issue during the hold itself.

When can I restart after surgery? Most patients restart 2 to 4 weeks post-operatively once fully mobile with no active bleeding or clot concerns; some orthopedic recoveries push this to around 6 weeks. This should be an explicit order, not an assumption.

Is there a non-hormonal option for hot flashes during the hold? Fezolinetant (Veozah) and low-dose paroxetine (Brisdelle) are FDA-approved for vasomotor symptoms; gabapentin is used off-label with trial support for sleep-disrupting hot flashes. Discuss these at the same visit where the hold is planned.

What if my surgery is urgent and there is no time for a hold? In urgent or emergency surgery, the hold is not applicable. The anesthesia and surgical teams manage VTE risk directly through mechanical and pharmacologic prophylaxis regardless of hormone status.

When to seek urgent care

Contact your surgical team or seek urgent care if, during the hold or after restart, you develop calf swelling or pain, sudden shortness of breath, chest pain, heavy or prolonged vaginal bleeding, or signs of a wound hematoma. These can indicate VTE or a surgical complication that needs prompt evaluation rather than a wait-and-see approach.

A note on the evidence behind this page

Oral micronized progesterone is addressed in menopause society guidelines and supported by both older randomized trials and observational hormone-therapy data. While prior guideline versions cited specific relative-risk values, patient numbers from named trials, and precise effect sizes for this agent, we were unable to trace these figures to verified primary sources for this draft and have therefore presented them in general rather than exact terms. Dosing and absorption information derives from the FDA-approved Prometrium label, which serves as a stable and verifiable regulatory reference. Prior to publication, an editor or clinician with access to primary literature should validate any numerical claim that readers may depend upon, especially the VTE relative-risk data and the vasomotor symptom trial outcomes, and either supply the properly matched source or retain the general phrasing.

References

1. Prometrium (progesterone) capsules, prescribing information. U.S. Food and Drug Administration label (verify current revision directly with the FDA before citing specific figures).

Additional claims describing observational VTE research, the PEPI trial, and vasomotor-symptom trial data are described in general terms in this article because the specific identifiers previously associated with them could not be verified. These require confirmation against the primary literature before any precise number is published.